NCT07349212 UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
| NCT ID | NCT07349212 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Ukko Inc |
| Condition | Peanut-Induced Anaphylaxis |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-02-18 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 40 participants in total. It began in 2026-02-18 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.
Eligibility Criteria
Inclusion Criteria: * Adults 18-55 years old * documented history of physician-diagnosed peanut allergy * positive skin prick test (SPT) * screening DBPCFC peanut protein * contraception use should be consistent with local regulations * capable of providing signed written informed consent Exclusion Criteria: * asthma based on NHLBI * uncontrolled cardiovascular disease * chronic disease history * exacerbation of dermatological conditions * life threatening episodes of anaphylaxis * active infections * poor physical or blood chemistry * immunodeficiency, bleeding disorders, malignancies * hypersensitivities to epinephrine, inactive ingredients in therapy * pregnant or breast feeding
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07349212 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Peanut-Induced Anaphylaxis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07349212 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07349212 currently recruiting?
Yes, NCT07349212 is actively recruiting participants. Contact the research team at sharron@ukko.us for enrollment information.
Where is the NCT07349212 trial being conducted?
This trial is being conducted at Camperdown, Australia, Bedford Park, Australia, Fitzroy, Australia, Perth, Australia and 1 additional location.
Who is sponsoring the NCT07349212 clinical trial?
NCT07349212 is sponsored by Ukko Inc. The trial plans to enroll 40 participants.